NASDAQ · PHARMACEUTICAL PREPARATIONS · LARGE CAP
ANI Pharmaceuticals, Inc. ANIP
17 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$883.4M
▲ 43.8% vs FY2024
EPS · FY25
—
Dividend / sh · FY25
—
Payout · FY25
1%
ROE · FY25
16.6%
Net margin · FY25
8.9%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 883.4M
Revenue, FY2025 · full 17-year series below
Revenue
Net income
9 cents of every revenue dollar became profit this year.
Per share
—
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
16.6%
Return on equity, FY2025
ROE
Operating margin12.6%
Net margin8.9%
Return on assets5.7%
Each USD of equity produced 17 cents of profit this year.
Returned to shareholders
USD 13.4M
returned in FY2025 · dividends + net buybacks
Dividends paidUSD 1.2M
Net buybacksUSD 12.2M
Share of profit17.1%
Consecutive raises—
USD 1.2M in dividends and USD 12.2M in buybacks — 17% of the year's profit went back to shareholders.
Growth
+33.5% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+40.8%
+33.5%
+27.7%
+48.0%
Net income
+17.7%
EPS, diluted
+9.7%
Returned to shareholders
+55.1%
+71.3%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 1.4B
total assets, end of FY2025
Total assetsUSD 1.4B
EquityUSD 540.7M
CashUSD 285.6M
Gross debtUSD 309.1M
Net debtUSD 23.5M
Current ratio2.71×
Net debt stands at 4% of equity.
History
17 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
Revenue $B
0.9
0.6
0.5
0.3
0.2
0.2
0.2
0.2
0.2
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
Operating income $B
0.1
0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
−0.0
−0.1
−0.0
·
EBITDA $B
0.1
0.0
0.1
−0.0
−0.0
−0.0
0.1
0.1
0.1
0.0
0.0
0.0
0.0
0.0
−0.1
−0.0
·
Income tax $B
0.0
−0.0
0.0
−0.0
−0.0
−0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
0.0
−0.0
·
·
·
Net income $B
0.1
−0.0
0.0
−0.0
−0.0
−0.0
0.0
0.0
−0.0
0.0
0.0
0.0
0.0
−0.0
−0.1
−0.0
−0.0
EPS, diluted $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
1
−9
9
−3
−0
−0
0
·
·
·
·
·
·
·
·
·
·
ROE %
16.6
−4.4
5.0
−14.8
−16.1
−11.0
3.0
8.3
−0.6
2.4
10.3
31.8
·
·
·
−264.1
−300.2
Shares out B
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
46 of 49
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 3 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed